The US President has intensified trade tensions by launching a new tariff measure targeting the global pharmaceutical sector. In a significant policy shift, the United States has announced tariffs of up to 100% on patented drugs, while temporarily exempting generic medicines from the new duties. The decision is expected to influence global pharmaceutical trade, pricing strategies, and access to high-cost branded medicines. Industry experts believe the move could reshape supply chains and force multinational drug companies to reconsider their global manufacturing and pricing strategies.
Policy Linked to National Security Concerns
The tariff order, issued on April 2, 2026, follows a Section 232 investigation that the US government initiated in May 2025. Authorities launched the probe to examine whether America’s dependence on imported pharmaceuticals poses a national security risk.
Under Section 232 of US trade law, the government can impose tariffs or restrictions if imports threaten national security. By invoking this provision, the US administration aims to reduce reliance on foreign drug supplies and encourage domestic pharmaceutical manufacturing. As a result, the policy marks a strategic shift in how the US plans to manage its pharmaceutical supply chain and pricing pressures.
Major Pharmaceutical Exporters Likely to Be Affected
The new tariffs will primarily impact countries that export high-value patented medicines to the United States. Key pharmaceutical exporters expected to feel the impact include Ireland, Germany, Switzerland, Belgium, Denmark, United Kingdom and Japan. Even countries with existing trade arrangements with the US will not receive special exemptions. For instance, European Union member states and Japan will remain subject to the tariff measures despite their trade partnerships with Washington. This indicates that the policy targets product categories rather than specific countries.
Generics Exempted to Avoid Drug Shortages
While the tariffs target patented medicines, generic drugs remain exempt for now. The US government took this step to prevent supply disruptions and avoid a sudden spike in medicine prices. Generic medicines play a dominant role in the US healthcare system. In fact, they account for more than 90% of all prescriptions filled in the country. Any restriction on generics could therefore lead to shortages and increase healthcare costs for millions of patients. However, policymakers have not ruled out the possibility that generics could be included in future tariff actions.
Limited Immediate Impact on India
For India, the direct impact of the tariff move appears relatively limited at present. The reason lies in the structure of India’s pharmaceutical exports to the US. Approximately 90% of India’s pharma exports to the United States consist of generic medicines, which are currently exempt from the tariff regime. In 2025, India exported pharmaceutical products worth $9.7 billion to the US, making it one of the largest suppliers of affordable medicines to the American market. Therefore, the immediate trade disruption for Indian pharmaceutical companies is expected to remain modest.
Possible Impact on Indian Specialty Drug Makers
Despite the temporary protection for generics, some Indian companies may still face indirect challenges. Firms that manufacture branded medicines, specialty drugs, or active pharmaceutical ingredients (APIs) used in patented formulations could experience some impact.
Moreover, industry analysts caution that uncertainty remains over the long-term scope of the tariff policy. If the US government decides to extend tariffs to generic medicines in the future, Indian pharmaceutical exports could face greater pressure. Consequently, Indian drugmakers will closely monitor further developments in US trade policy.
Strategic Push for Domestic Drug Manufacturing
The tariff decision reflects a broader strategy by the US administration to reshape the pharmaceutical industry. By imposing high duties on imported patented drugs, the government aims to achieve several objectives simultaneously. First, it seeks to encourage pharmaceutical companies to lower drug prices in the US market. Second, the policy aims to promote domestic manufacturing of high-value medicines. Finally, it is designed to strengthen US control over pharmaceutical supply chains, particularly for critical drugs. Through these measures, the administration hopes to reduce long-term dependence on overseas pharmaceutical production.
Global Pharma Companies Likely to Adjust Strategies
In response to the new tariffs, global pharmaceutical companies are expected to explore several strategic options. Some companies may negotiate tariff reductions with US authorities, while others could revise their pricing models to offset the additional costs. In addition, multinational firms may consider expanding limited manufacturing operations within the United States to avoid import duties. As reported by news24online.com, as the policy evolves, the global pharmaceutical industry may witness significant adjustments in investment, production, and supply chain strategies.
